

Prof. Dr. VITTORIO PACE

Professore Ordinario di Chimica Organica Università degli Studi di Torino, Dipartimento di Chimica Via P. Giuria 7, 10125 Torino e-mail: <u>vittorio.pace@univie.ac.at; vittorio.pace@unito.it</u> X: @LabPace **ORCID ID**: 0000-0003-3037-5930

Biography

Vittorio Pace - since March 2020 - is Full Professor of Organic Chemistry at the University of Turin (Italy). He graduated in Pharmacy in 2005 from the University of Perugia and received the PhD in Chemical Sciences from the Complutense University of Madrid in 2010 under the guidance of Professor A. R. Alcántara. After postdoctoral training at Vienna (2010-2011, Prof. Holzer), Manchester (2011-2013, Prof. Procter) and Stockholm (2013-2014, Prof. Olofsson), he obtained a group leader position and a Tenure-Track Professorship at the University of Vienna.

In 2016 he received the *Habilitation* in Pharmaceutical Chemistry from the University of Vienna. He has been the recipient of a series of awards including the *Ciamician Medal* of the Italian Chemical Society, the *Caglioti Prize* of the Accademia Nazionale dei Lincei, the *Young Investigator Award* of the Faculty of Life Sciences at Vienna, the *La Roche-Hoffmann Prize* of the EFMC, the *Innitzer Award*, the *Habilitation Award* of the Austrian Chemical Society and, the *Thieme Journal Award* in 2020.

In 2022 he was admitted at the *Real Academia Nacional de Farmacia of Spain* and, since 2020 he is a member of the *European Pharmacopeia*. In 2022 he received the *Acreditación para Catedrático de Universidad (Area de Ciencias)* from ANECA.

His research core is represented by the design and development of new synthetic concepts with functionalized organometallic reagents with particular emphasis to homologation procedures. This work is crystallized in > 150 published papers. Prof. Pace supervised 12 doctoral theses and 50 MSc and BSc theses. He edited a two-volumes book for Wiley-VCH titled *"Homologation Reactions: Reagents, Applications, and Mechanisms"*, printed in July 2023.

In October 2024 he has been the recipient of a PRIN project, as PI, focusing on the introduction of enantiopure halogen-containing C1-synthons with vistas to applicative uses in medicinal chemistry.